Aridis Pharmaceuticals (NASDAQ: ARDS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.510 | -0.440 | 0.0700 | ||||
REV | 2.000M | 1.187M | -813.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Aridis Pharmaceuticals (NASDAQ: ARDS) through any online brokerage.
Other companies in Aridis Pharmaceuticals’s space includes: Allena Pharma (NASDAQ:ALNA), Indaptus Therapeutics (NASDAQ:INDP), TransCode Therapeutics (NASDAQ:RNAZ), CohBar (NASDAQ:CWBR) and RenovoRx (NASDAQ:RNXT).
The latest price target for Aridis Pharmaceuticals (NASDAQ: ARDS) was reported by HC Wainwright & Co. on Tuesday, July 20, 2021. The analyst firm set a price target for 19.00 expecting ARDS to rise to within 12 months (a possible 1627.27% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Aridis Pharmaceuticals (NASDAQ: ARDS) is $1.1 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Aridis Pharmaceuticals.
Aridis Pharmaceuticals’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Aridis Pharmaceuticals.
Aridis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.